Overview

Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease

Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
Drug serum concentrations will be measured at several time-points for inflammatory disease patients treated with anti-TNF agents. The purpose is to determine which patients that will clinically benefit from either discontinue treatment, adjusting the dose, switch to another anti-TNF agent or a different class of medication.
Details
Lead Sponsor:
Oslo University Hospital
Treatments:
Adalimumab
Certolizumab Pegol
Infliximab